At the last check on Thursday, Fortress Biotech Inc.’s (NASDAQ:FBIO) stock was down -$0.02, moving down -5.26 percent to $0.36. The average number of shares traded per day over the past five days has been 638,074 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0431 fall in that time frame. In the last twenty days, the average volume was 568,333, while in the previous 50 days, it was 655,643.
Since last month, FBIO stock retreated -38.36%. Shares of the company fell to $0.3111 on 08/31/23, the lowest level in the past month. A 52-week high of $1.16 was reached on 01/18/23 after having rallying from a 52-week low of $0.36. Since the beginning of this year, FBIO’s stock price has dropped by -45.04% or -$0.2921, and marked a new high 8 times. However, the stock has declined by -68.97% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
FBIO stock investors should be aware that Fortress Biotech Inc. (FBIO) stock had its last reported insider trading activity 13 days ago on Aug 18. ROSENWALD LINDSAY A MD, the President, CEO & Chairman of the company, purchased of 10,000 shares for $9.34 on Aug 18. It resulted in a $93,400 investment by the insider. ROSENWALD LINDSAY A MD added 10,000 shares at an average price of $11.75 on Aug 17. The insider now owns 102,500 shares following the transaction. On Feb 10, President, CEO & Chairman ROSENWALD LINDSAY A MD bought 2,395,209 shares at $0.83 apiece. The transaction was valued at $2,000,000.
Valuation Metrics
The stock’s beta is 2.08. Besides these, the trailing price-to-sales (P/S) ratio of 0.79, the price-to-book (PB) ratio of 2.12.
Financial Health
In the three months ended June 29, Fortress Biotech Inc.’s quick ratio stood at 0.90, while its current ratio was 1.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 2.53, and the total debt-to-equity ratio was 3.19. On the profitability front, the trailing twelve-month gross margin is 53.50% percent. Based on annual data, FBIO earned $44.97 million in gross profit and brought in $75.74 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -143.70%. Return on equity (ROE) for the past 12 months was -250.00%.
In Fortress Biotech Inc.’s quarter-end financial report for June 29, it reported total debt of $45.33 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. FBIO’s revenue fell -8.63% to $12.43 million during the quarter, while net income inched up to $17.39 million. While analysts expected Fortress Biotech Inc. to report -$0.23 quarterly earnings, the actual figure was -$0.24 per share, beating the consensus estimate by -4.30%. During the quarter, the company generated -$46.65 million in EBITDA. The liabilities of Fortress Biotech Inc. were 196.66 million at the end of its most recent quarter ended June 29, and its total debt was $84.42 million. The value of shareholders’ equity is $132.79 million.
Technical Picture
This quick technical analysis looks at Fortress Biotech Inc.’s (FBIO) price momentum. With a historical volatility rate of 47.63%, the RSI 9-day stood at 22.68% on 30 August.
With respect to its five-day moving average, the current Fortress Biotech Inc. price is down by -10.62% percent or -$0.0431. At present, FBIO shares trade -35.37% below its 20-day simple moving average and -50.39% percent below its 100-day simple moving average. However, the stock is currently trading approximately -39.52% below its SMA50 and -54.93% below its SMA200.
Stochastic coefficient K was 15.41% and Stochastic coefficient D was 11.22%, while ATR was 0.0449. Given the Stochastic reading of 20.98% for the 14-day period, the RSI (14) reading has been calculated as 28.42%. As of today, the MACD Oscillator reading stands at -0.0255, while the 14-day reading stands at -0.0498.
